Clinical trials: Parathyroid Dysfunction
Hypoparathyroidism
Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With Hypoparathyroidism
The purpose of this study is to evaluate the long-term safety and tolerability of MBX 2109 in patients with hypoparathyroidism who completed the 12-week treatment period in the Phase 2 study, MBX-2H1002.
- Trial name
- NCT06531941
- Testing
- 400 µg of MBX 2109 once-weekly by subcutaneous injection, 200-1600 µg of MBX 2109 once-weekly by subcutaneous injection
- Where
- 23 sites in United States, Argentina and 1 more
- Volunteers
- 60 people
- Sponsor
- MBX Biosciences
Postmenopausal Osteoporosis, Postmenopause
Frequency of Hyperparathyroidism in Postmenopausal Osteoporosis and Its Treatment
Recently, an increase in the prevalence of hyperparathyroidism and hypovitaminosis D in postmenopause women has been occurring in Mexico and the world.
- Conditions
- Postmenopausal Osteoporosis, Postmenopause, Hyperparathyroidism, Secondary, Hypovitaminosis D
- Trial name
- NCT05347082
- Testing
- Cholecalciferol
- Where
- Mexico
- Volunteers
- 47 people
- Sponsor
- Hospital Regional 1o de Octubre
Hyperparathyroidism, Chronic Kidney Disease
Sevelamer and Secondary Hyperparathyroidism in Chronic Kidney Disease
The hypothesis underlying this study is that phosphate interferes with PTH-mediated calcium reabsorption in the distal nephron and thereby necessitates supranormal [PTH]to maintain normocalcemia in chronic kidney disease.
- Trial name
- NCT01191762
- Testing
- sevelamer carbonate
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Kenneth R. Phelps, M.D.
Phosphorus and Calcium Disorders, Parathyroid Diseases
Serum Calcium to Phosphorous (Ca/P) Ratio in the Diagnosis of Ca-P Metabolism Disorders: a Multicentre Study
Primary hyperparathyroidism (PHPT) and Hypoparathyroidism (HP) are two of the most frequent disorder of Calcium-Phosphorus (Ca-P) metabolism.
- Conditions
- Phosphorus and Calcium Disorders, Parathyroid Diseases, Hyperparathyroidism, Hypoparathyroidism
- Trial name
- NCT03747029
- Testing
- No intervention is provided
- Where
- Italy
- Volunteers
- 1,038 people, healthy volunteers welcome
- Sponsor
- Azienda Ospedaliero-Universitaria di Modena
Complete DiGeorge Anomaly, DiGeorge Syndrome
Thymus Transplantation Safety-Efficacy
Complete DiGeorge anomaly (cDGA) is a disorder in which there is no thymus function. With no thymus function, bone marrow stem cells do not develop into educated T cells, which fight infection.
- Conditions
- Complete DiGeorge Anomaly, DiGeorge Syndrome, DiGeorge Anomaly, Complete DiGeorge Syndrome
- Trial name
- NCT01220531
- Testing
- Cultured Thymus Tissue
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Sumitomo Pharma Switzerland GmbH
Hyperparathyroidism, Primary, Osteoporosis
Efficacy of Cinacalcet in the Control of Primary Hyperparathyroidism
To assess the efficacy and safety of treatment with cinacalcet and with cinacalcet plus alendronate in controlling bone loss induced by primary hyperparathyroidism.
- Trial name
- CA-PHP (NCT02417389)
- Testing
- cinacalcet, Alendronate
- Where
- Italy
- Volunteers
- 22 people
- Sponsor
- Istituto Auxologico Italiano
Hyperparathyroidism, Disorders of Parathyroid Gland
Efficacy and Safety of Ultrasonic Ablation to Treat Secondary Hyperparathyroidism in Chronic Kidney Disease Patients
It is difficulty for the treatment of secondary hyperparathyroidism in the chronic kidney disease (CKD) patients who had not succeeded medical therapy and could not get parathyroidectomy.
- Trial name
- NCT01640184
- Testing
- Parathyroidectomy, Active vitamin D, Ultrasonic ablation
- Where
- 2 sites in China
- Volunteers
- 79 people
- Sponsor
- Dongliang Zhang, MD
DiGeorge Syndrome, Congenital Heart Defects
Infection in DiGeorge Following CHD Surgery
We propose a retrospective review of patients with DiGeorge syndrome having undergone cardiac surgery to evaluate the incidence of blood stream and/or surgical site infection.
- Trial name
- NCT00278005
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Children's Healthcare of Atlanta
Secondary Hyperparathyroidism, Chronic Kidney Disease
Paricalcitol Versus Calcitriol for Efficacy and Safety in Stage 3/4 Chronic Kidney Disease (CKD) With Secondary Hyperparathyroidism (SHPT)
Secondary Hyperparathyroidism (SHPT) occurs in many patients with kidney disease and leads to bone disease. Active forms of vitamin D, calcitriol and paricalcitol, treat SHPT, but may have different effects on blood calcium.
- Trial name
- PACE (NCT00823303)
- Testing
- Paricalcitol, Calcitriol
- Where
- 4 sites in United States
- Volunteers
- 110 people
- Sponsor
- Washington University School of Medicine
Hyperparathyroidism, Hypercalcemia
Studies of Elevated Parathyroid Activity
Observational Phase: Patients whose parathyroid activity is elevated above normal are referred to as having hyperparathyroidism.
- Conditions
- Hyperparathyroidism, Hypercalcemia, Parathyroid Neoplasm, Multiple Endocrine Neoplasia
- Trial name
- NCT00001277
- Testing
- 68Ga-Dotatate, 18F-DOPA
- Where
- United States
- Volunteers
- 1,553 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Kidney Diseases, Dialysis; Complications
PRevEnting FracturEs in REnal Disease - 1
PREFERRED-1 is a pilot study designed to determine the feasibility of a large randomized, pragmatic, open-label, comparative-effectiveness trial of denosumab for the prevention of fragility fractures in people receiving…
- Conditions
- Kidney Diseases, Dialysis; Complications, Fragility Fracture, Chronic Kidney Disease-Mineral and Bone Disorder
- Trial name
- PREFERRED-1 (NCT05096195)
- Testing
- Denosumab 60 mg/ml, Calcium and vitamin D prophylaxis, Monitoring of post-injection calcium and phosphate
- Where
- 6 sites in Canada
- Volunteers
- 60 people
- Sponsor
- Western University, Canada
Hyperparathyroidism
A Prospective Cohort Study to Describe the Evolution of Persistent Hyperparathyroidism in Kidney Transplant Recipients
The purpose of this study is to see if Hyperparathyroidism (HPT) is common in people who receive a kidney transplant. Patients with HPT often have high parathyroid hormone (PTH) levels and may have large parathyroid glands in the…
- Trial name
- NCT01163669
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- The Cleveland Clinic
Hyperparathyroidism
NUclear MEdicine DIagnostic and Artificial Intelligence
Artificial intelligence algorithms for parathyroid adenoma detection in parathyroid scans The aim of the study is to develop programs for the automatic subtraction of planar and tomographic parathyroid images and for the…
- Trial name
- NUMEDIA (NCT05963841)
- Testing
- treatment program
- Where
- France
- Volunteers
- 1 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Hypoparathyroidism
A Cohort Study on the Safety and Efficacy of XH-02 in Treating Hypoparathyroidism
XH-02 is an mRNA nucleic acid drug that expresses PTH in the body following intravenous or subcutaneous injection, providing PTH replacement therapy for patients with hypoparathyroidism.
- Trial name
- NCT07540286
- Testing
- Single subcutaneous injection, Multiple subcutaneous injection
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking Union Medical College Hospital
22q11 Deletion Syndrome
NB-001 in Children and Adolescents With 22q11 Deletion Syndrome
This is a Phase 2, randomized, placebo-controlled crossover trial to assess the safety and efficacy of NB-001 in children and adolescents with 22q11DS that manifest commonly associated neuropsychiatric symptoms.
- Trial name
- NCT05290493
- Testing
- NB-001
- Where
- 4 sites in United States, Canada
- Volunteers
- 37 people
- Sponsor
- Nobias Therapeutics, Inc.
Secondary Hyperparathyroidism
A Study of SHR6508 in Secondary Hyperparathyroidism
The study is being conducted to evaluate the efficacy and safety of SHR6508 for Chinese patients with secondary hyperparathyroidism of chronic kidney disease treated by maintenance hemodialysis.
- Trial name
- NCT05663411
- Testing
- SHR6508, Cinacalcet
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Primary Hyperparathyroidism
Effects of Parathyroidectomy on Cardiovascular Risk Factors in Primary Hyperparathyroidism
Primary hyperparathyroidism (PHPT) is associated with increased cardiovascular morbidity. The benefit of surgical treatment in this respect is unclear.
- Trial name
- NCT01057732
- Where
- Israel
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- HaEmek Medical Center, Israel
Primary Hyperparathyroidism, Primary Hyperparathyroidism Due to Adenoma
Aldosterone Variations in Patients With Primary Hyperparathyroidism After Surgery
Primary hyperparathyroidism is a disorder of calcium and phosphorus metabolism linked to dysfunction of one or more parathyroid glands.
- Trial name
- ALDOPARA2 (NCT07388914)
- Where
- France
- Volunteers
- 400 people
- Sponsor
- Central Hospital, Nancy, France
CKD Stage 3, CKD Stage 4
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability Evaluation of CTAP101 Extended-release Capsules in Pediatric Participants
The goal of this clinical trial is to evaluate safety, tolerability, and how CTAP101 Capsules work to treat Pediatric Participants with Secondary Hyperparathyroidism, Stage 3 or 4 Chronic Kidney Disease and Vitamin D…
- Conditions
- CKD Stage 3, CKD Stage 4, Secondary Hyperparathyroidism, VDI
- Trial name
- NCT07494045
- Testing
- CTAP101
- Where
- 5 sites in United States
- Volunteers
- 40 people
- Sponsor
- OPKO Health, Inc.
Hyperparathyroidism, Hypercalcemia
Oral Peptones Load in Normocalcemic and Hypercalcemic Primary Hyperparathyroidism and Healthy Subjects
The purpose of this study is to assess if subjects with hyperparathyroidism with normal serum calcium levels have different responses in the calcium regulating hormonal handling compared to a) patients with primary…
- Trial name
- NCT01042626
- Testing
- Oral peptones load
- Where
- Italy
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Eastern Piedmont